The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Patient-reported QoL outcomes with venetoclax-based first-line combinations in the GAIA/CLL13 trial
Moritz Fürstenau, MD, University Hospital of Cologne, Cologne, Germany, discusses an analysis of patient-reported quality of life (QoL) data from the Phase III GAIA/CLL13 trial (NCT02950051), which evaluated the efficacy of venetoclax-based combinations in the first-line treatment of patients with chronic lymphocytic leukemia (CLL). Dr Fürstenau highlights that improvements in QoL were observed in all four treatment arms, including the placebo arm. However, notable differences were reported in the timing of these improvements between the treatment groups. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
